Cetuximab, a human-mouse chimeric IgG1 mAb targeting epidermal growth factor receptor (EGFR), is the first mAb drug approved for treating patients with irinotecan-refractory and/or oxaliplatin-refractory metastatic colorectal cancer (mCRC)13. The gene discussed is EGFR; the disease is metastatic colorectal cancer.